Men's Health Briefing: October 19, 2026

The short version

A quiet week. We found no new FDA, DEA, FTC, or federal telehealth actions on men's health since our October 13 briefing.

Health topics: a retrospective study at Memorial Sloan Kettering found no clear difference in prostate cancer progression between 79 men on testosterone therapy and the rest of 3,324 men on active surveillance. It is a small, single-center, observational result.

Health topics: a cohort of 313,953 adults found sleep apnea was associated with a higher chance of later insomnia.

The DEA's final telehealth prescribing rule has not been published as of this check. The temporary rules expire December 31, 2026.

This week

We checked FDA, DEA, and FTC announcements, federal telehealth policy, research news, and news on the providers in our directory for October 14 – 19. We found nothing in that window that we could confirm with a primary source and that changes treatment access, cost, safety, or health data for men's health readers. The FDA press announcements we found dated October 14 concern a rare disease drug-development framework and a bladder cancer approval. The FTC's October 15 releases concern a ticket broker and consumer refunds in a wire-transfer case; none concerns men's health products or telehealth. Medicare telehealth coverage remains in place through December 31, 2027. For the previous check, see our October 13 briefing.

Health topics

Testosterone & TRTAugust 24, 2026

Testosterone therapy in men on prostate cancer active surveillance: no clear difference in progression in a single-center study

Researchers at Memorial Sloan Kettering Cancer Center reviewed records of 3,324 men with grade group 1 or 2 prostate cancer who were on active surveillance, 79 of whom were also receiving testosterone therapy. The study, published online in The Journal of Urology on August 24, 2026, found that testosterone therapy was not significantly associated with progression on biopsy (hazard ratio 0.99, 95% confidence interval 0.67 to 1.48) or with progression to definitive treatment (hazard ratio 0.94, interval 0.64 to 1.38). Overall, 1,256 men (38%) had progression on biopsy. The authors concluded that testosterone therapy can be used in these men with careful monitoring.

The limits matter. This was a retrospective record review, not a randomized trial, and only 79 men were on testosterone, so the confidence intervals are wide: the data are compatible with a modest increase or decrease in risk. The abstract does not give follow-up time, and the authors themselves call for larger studies with longer follow-up. It was done at one cancer center, which closely monitored the men. We read the abstract; we did not have access to the full text, funding, or conflict-of-interest statements.

What it means for youThis adds one data point to a debated question; it does not settle it. If you have prostate cancer, or a rising PSA, and are considering or already using testosterone therapy, that is a decision for your urologist and prescriber together, with regular PSA monitoring. Don't change any treatment based on one study.

Sources: PubMed record · DOI · Related: Testosterone and TRT guide · TRT side effects and monitoring

SleepSeptember 24, 2026

Sleep apnea linked to a higher chance of later insomnia in a large health-system cohort

A retrospective cohort study in the journal Sleep, published online September 24, 2026, used University of Michigan Health System records (2012–2023) for 313,953 adults aged 40 to 85. After adjusting for age, sex, race and ethnicity, BMI, and neighborhood deprivation, people with obstructive sleep apnea (OSA) had a higher rate of new insomnia diagnoses. The hazard ratios were 1.39 (95% CI 1.35 to 1.43) in White, 1.57 (1.45 to 1.70) in Black, and 1.57 (1.34 to 1.84) in Arab adults. The association did not differ by sex.

The limits matter. This was an observational look at medical records, so it shows an association, not that sleep apnea causes insomnia, and diagnoses recorded in a health system can miss people who were never tested or never reported symptoms. The study included women and men, and the abstract does not report results for men alone. We read the abstract only.

What it means for youSleep apnea and insomnia can overlap and can look alike: poor sleep, waking tired, trouble staying asleep. If you have persistent sleep trouble, along with snoring, gasping, or heavy daytime sleepiness, mention all of it to your doctor, since sleep apnea can only be diagnosed with a sleep test.

Sources: PubMed record · Related: Sleep apnea in men · Sleep aids

What we're watching

The DEA's final telemedicine rule, which was sent to the White House Office of Management and Budget on August 25, 2026. The federal regulatory agenda lists November 2026 for final action, ahead of the December 31 expiration of the temporary telehealth prescribing rules. We found no publication of the rule as of October 19. If you get testosterone through a telehealth-only provider, nothing has changed yet. (NASCSA)

Testosterone for women, following the FDA's September 17 public workshop. Comments were open through October 19, 2026. (Public comment docket)

Testosterone label updates as manufacturers revise their prescribing information after the FDA's June 2026 request. See our TRT guide for what the research shows.

Compounded GLP-1 enforcement, including any follow-up to the FDA's September 18 warning letter to Empower Pharmacy, which the FDA made public on September 22. A warning letter states the FDA's concerns and is not a final finding. (Buchanan Ingersoll & Rooney · Related: our GLP-1 guide)

The FTC's case against Hims & Hers, filed July 29, 2026. The allegations have not been proven, and the company has said it disputes them. (FTC case page · Our Hims review)